R&D of Nobelpharma
Since the start of the business, Nobelpharma has been focusing on the research and development of drugs for unmet medical needs that other pharmaceutical companies do not engage in.
Our research and development themes are selected with priority on those strongly requested by patient groups and academic societies, which are mainly orphan drugs (drugs for rare diseases) , off-label drugs, or pediatric medicines.
We are determined to further enhance our research and development system by stepping into drugs under new concepts and with a view to our globalization.
Reasons for top-level numbers of orphan designations and new drug approvals in Japan
Despite being a small company in business for just over 15 years with less than 350 employees, we have implemented the business scheme of specializing in orphan drugs and accomplished to be in top class in Japan on par with major pharmaceutical companies in each number of orphan drug designations (November 2003 - December 2019) and new drug approvals (2008 - 2019: in-house data).
How is this possible?
The reason is our capability of searching and developing drugs and medical devices in the needs oriented approach.
1. Patient Needs First
Many of the pharmaceutical companies and ventures start their development of new drugs based on the research results of their own or universities, “seeds first” in other words.
On the other hand, “the patient needs comes first” for us. Placing top priority on serving such needs, we take the shortest path for development to “make the drugs available quickly.”
What we should also note is the fact that the active support from patients, specialty physicians, and medical institutions undoubtedly provides us the significant driving force.
2. Specializing in Later-phase Development
Although we are a pharmaceutical company, we do not have any laboratories. Our so-called researchers without white coats engaged in seeds searching evaluate the information collected from all around the world and determine the drugs that should be developed for patients in Japan.
This significantly reduces the time required for early-phase development allowing us to focus on later-phase development, which contributes to our fast development speed and frequent approvals.
3. Specific "Schedule Management"
Our staff members set a deadline at the beginning before undertaking each task and those in research and development are no exceptions laying our specific timelines.
Each staff member always sets exact “dates” according to schedules for clinical trials, application filings, and expected approvals (Go to Pipeline), self-declaring the completion by specific “day, month, and year” no matter how long away and conducting oneself toward such a goal.
This does not mean we are forced to keep the schedule even if it becomes unreasonable. As we constantly confirm whether it is carried out on schedule in a relatively short span of time, we set a new “date” whenever the schedule seems unrealistic and make steady progress in development taking a proactive approach.
4. Maintaining Pleasant Working Environment for Select Few
It is also our characteristic to have many experienced staff members, and the average age is rather high in the 50’s.
With experiences in approval processes gained at major pharmaceutical companies, they know how to accomplish goals with the shortest route by utilizing their pertinent and extensive contacts acquired through many years of expetise.
Our capability of research and development continues to enhance as such staff members fully display their skills and enthusiastically work every day on site.